3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Lymphoma
2
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
209
fludarabine phosphate
184
Azacitidine
159
fludarabine
142
Busulfan
138
Tacrolimus
119
Mycophenolic Acid
111
Cytarabine
110
Whole-Body Irradiation
106
Peripheral Blood Stem Cell Transplantation
98
Antilymphocyte Serum
97
Melphalan
90
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
42
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Injections
27
Biopsy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Myelodysplastic Syndromes
×
Immunotherapy, Active
×
Clear all
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled